Roswell Park Cancer Institute clinical trial pipeline

9 trials changed in the last 30 days: 0 stopped, 5 with notable changes, 4 with minor changes only.

1. Notable

   Propranolol With Chemotherapy or Chemoradiation for Esophageal…Propranolol With Chemotherapy or Chemoradiation for Esophageal Adenocarcinoma

   Primary completion pushed from Apr 1, 2029 to Apr 1, 2031

   Also in this update: Study completion pushed from Apr 1, 2029 to Apr 1, 2036

   Roswell Park Cancer Institute·Phase 2· NCT04682158· Registry history of NCT04682158 on ClinicalTrials.gov (opens the registry)

   Oct 22, 2026

2. Notable

   Fluorescence Image Guided Surgery Followed by Intraoperative…Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control · Locally Advanced or Recurrent Colorectal Cancer

   Primary and study completion pushed from Jun 1, 2027 to Jun 1, 2029

   Roswell Park Cancer Institute·Phase 1/2· NCT06307548· Registry history of NCT06307548 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

3. Notable

   Belantamab Mafodotin and Lenalidomide · Multiple Myeloma in…Belantamab Mafodotin and Lenalidomide · Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

   Primary completion pushed from Oct 21, 2026 to Jul 29, 2027

   Also in this update: Study completion moved earlier from Sep 1, 2029 to Jul 29, 2027; and 1 more change in the last 30 days

   Roswell Park Cancer Institute·Phase 2· NCT04876248· Registry history of NCT04876248 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

4. Notable

   Temozolomide and Survivin Long Peptide Vaccine (SurVaxM)…Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) · Progressing Metastatic Neuroendocrine Carcinomas

   Trial status changed: Suspended → Not Yet Recruiting

   Roswell Park Cancer Institute·Phase 2· NCT06202066· Registry history of NCT06202066 on ClinicalTrials.gov (opens the registry)

   Oct 20, 2026

5. Notable

   GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal…GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

   Enrollment increased: 18 → 33 participants

   Roswell Park Cancer Institute·Phase 1· NCT07489287· Registry history of NCT07489287 on ClinicalTrials.gov (opens the registry)

   Oct 22, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.